DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• DNA double-strand breaks (DSBs) are lethal DNA lesions targeted by many cancer therapies.
• Cancer cells possess robust DNA repair mechanisms, primarily Non-Homologous End Joining (NHEJ) and Homologous Recombination Repair (HRR), which can reduce chemotherapy efficacy.

Purpose of the Study:

• To review recent advances in targeting DNA double-strand break repair pathways for anticancer therapy.
• To highlight the potential of DNA repair inhibitors as a novel class of anticancer drugs.

Main Methods:

• Literature review of current research on DNA double-strand break repair pathways.
• Analysis of therapeutic strategies involving DNA damage and repair inhibition.
• Discussion of emerging trends in anticancer drug development, including PARP inhibitors and DNA repair inhibitors.

Main Results:

• Anticancer therapies often induce DNA double-strand breaks, but cancer cells' repair systems counteract these effects.
• Inhibiting DNA repair pathways like NHEJ and HRR presents a viable strategy to sensitize cancer cells to existing therapies.
• The success of Poly (ADP-ribose) polymerase (PARP) inhibitors validates targeting DNA repair as a therapeutic approach.

Conclusions:

• Targeting DNA double-strand break repair pathways is a promising frontier in oncology.
• Development of specific inhibitors for NHEJ and HRR holds significant potential for creating next-generation anticancer drugs.
• This approach offers new opportunities to overcome therapeutic resistance in cancer treatment.